Aizen Therapeutics
Aizen Therapeutics is a biotechnology company pioneering the development of Mirror Peptides, a novel class of synthetic, fully D-amino acid peptides that offer superior therapeutic stability and reduced immunogenicity compared to natural peptides. Their proprietary DaX™ platform, leveraging generative AI and advanced computational models, enables rapid design-build-test cycles (~4 weeks) with high hit rates for drug development targeting neurological disorders, oncology, and genetic diseases. This platform enhances drug specificity, half-life, and solubility, positioning Aizen as a leader in next-generation peptide therapeutics with a focus on improving patient safety and efficacy.
Aizen Therapeutics
Aizen Therapeutics is a biotechnology company pioneering the development of Mirror Peptides, a novel class of synthetic, fully D-amino acid peptides that offer superior therapeutic stability and reduced immunogenicity compared to natural peptides. Their proprietary DaX™ platform, leveraging generative AI and advanced computational models, enables rapid design-build-test cycles (~4 weeks) with high hit rates for drug development targeting neurological disorders, oncology, and genetic diseases. This platform enhances drug specificity, half-life, and solubility, positioning Aizen as a leader in next-generation peptide therapeutics with a focus on improving patient safety and efficacy.
TL;DR
Founded: 2022 (Caltech spinout)
Headquarters: San Diego, CA
Core technology: DaX™ generative AI platform for D‑amino‑acid (Mirror) peptides
Therapeutic focus: Neurological disorders, oncology, genetic diseases; oral biologics
Recent financing: $13.0M seed (Nov 2024)
Related Companies
| Company |
|---|
 |
 |
 |
 |
 |
Company Overview
Problem Domain
Designing next‑generation peptide therapeutics that overcome limitations of natural peptides (stability, immunogenicity, oral delivery).
Founded
2022
Industry
Biotechnology
Tech Stack
Funding Track Record
$13,000,000
Round announced November 2024 with participation from Wilson Hill Ventures and Cercano Management.
Investor Signal
“Madrona Venture Group led seed; participation from Wilson Hill Ventures and Cercano Management”